证券之星消息，10月18日发布《宏利红利先锋混合型证券投资基金分红公告》。2025年度第1次分红。 公告显示，本次分红的收益分配基准日为9月9日，详细分红方案如下： | 分级基金筒称 | 代码 | 基准日基金净值 | | 分红方案 | | | --- | --- | --- | --- | --- | --- | | | | (元) | | (元/10份) | | | 宏利红利牛锋混合A 162212 | | | 1.08 | | 0.08 | | 宏利红利先锋混合C 015619 | | | 1.06 | | 0.06 | 本次分红对象为权益登记日在宏利基金管理有限公司登记在册的本基金全体份额持有人。，权益登记日 为10月21日，现金红利发放日为10月22日。选择红利再投资方式的投资者所转换的基金份额将以2025年 10月22日的基金份额净值为计算基准确定再投资份额，本公司于2025年10月23日对红利再投资所转换的 基金份额进行确认并通知各销售机构。2025年10月24日起投资者可以查询。根据财政部、国家税务总局 的财税字［2002］128号《财政部、国家税务总局关于开放式证券投资基金有关税收问题的通知》 ...

注:1、本基金限制大额申购金额为：100万元（不含100万元），暂停起始日为2025年10月17日。 2、本基金恢复大额申购、大额定期定额投资、大额转换转入业务的具体时间将另行公告。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，10月16日宏利基金管理有限公司发布《宏利红利先锋混合型证券投资基金暂停接受大额 申购、大额转换转入及大额定期定额投资业务的公告》。公告中提示，为充分保护基金份额持有人利 益，保障基金平稳运作，自2025年10月17日起宏利红利先锋混合型证券投资基金暂停接受大额申购、大 额转换转入及大额定期定额投资业务，下属分级基金调整明细如下： | 分级基金筒称 代码 | | 是否暂停（大额）申购 申购限额 转入限额 定投限额 | | | | --- | --- | --- | --- | --- | | | (转入转出、赎回、定投) | (元) | (元) | （元） | | 宏利红利先锋混合A 162212 | 를 | 100.00万 | 100.00万 | | | 宏利红利先锋混合C 015619 ...

Core Viewpoint - The AI Fund Manulife Dividend Pioneer Mixed A (162212) reported a profit of 942,000 yuan for Q2 2025, with a weighted average profit per fund share of 0.0171 yuan, and a net value growth rate of 1.98% during the reporting period [3][17]. Fund Performance - As of July 18, the fund's unit net value was 0.989 yuan, with a one-year cumulative growth rate of 8.09%, ranking 127 out of 133 comparable funds [3][4]. - The fund's three-month cumulative growth rate was 12.64%, ranking 119 out of 138 comparable funds, and the six-month growth rate was 10.13%, ranking 132 out of 138 [4]. Investment Strategy - The fund focuses on long-term investments in pharmaceutical and medical stocks, targeting companies with sustainable dividend capabilities and strong fundamentals [3]. - As of Q2 2025, the fund's main investments were concentrated in sectors such as in-hospital medical devices, equipment and consumables, in-hospital pharmaceuticals, and medical consumer products [3]. Risk Metrics - The fund's three-year Sharpe ratio was -0.0246, ranking 61 out of 105 comparable funds [10]. - The maximum drawdown over the past three years was 27.61%, with the largest single-quarter drawdown occurring in Q1 2022 at 21.42% [12]. Fund Composition - As of Q2 2025, the fund's total assets amounted to 50.68 million yuan [17]. - The top ten holdings included companies such as Aohua Endoscopy, Huatai Medical, and Heng Rui Medicine [19]. Portfolio Management - The fund has maintained a high average stock position of 92.95% over the past three years, compared to a comparable average of 86.95% [15].